ResMed management check
RMD · Health Care · Health Care Equipment · CEO Michael J. Farrell
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2022
4551stDetail
$100 invested at the start of fiscal 2022 grew to $79, against $82 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9274thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.85 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch1.1% of net income
What does the CEO cost owners?
$16.2m pay · $1.5bn net income, FY2026
4848thDetail
$16.2m of reported pay in fiscal 2026, against $1.5bn of net income.
- GoodCEO stake ≈ 6.9 years of pay
Do they own the stock?
476,419 shares ≈ $111.5m
6 mo: ▲ $0 bought · ▼ $8.7m sold
7778thDetail
The CEO holds 476,419 shares, directly or through trusts (unvested awards not counted): about 6.9 years of pay. Light activity: no buys, $8.7m sold in six months. 10 of 10 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −0.0% a year; flagged above +2%
Stock pay 1.8% of revenue
5036thDetail
Diluted shares changed -0.0% a year over the last three fiscal years. Stock-based pay was 1.8% of revenue in the latest year.
- Good6 leadership filings in 3 years
Is leadership stable?
6 filings under 8-K 5.02 in 3 years
CEO: Mr. Michael Farrell
9575thDetail
CEO in the pay table: Mr. Michael Farrell. 6 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- FlagRed flags on file
Are the books clean?
Since 2021
- 0Restated
- 1Auditor changes
- 0Late filings
- 010-K amended
307thDetail
1 auditor change (8-K 4.01) since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed October 1, 2026.
Pay tied most to Adjusted Net Sales
Other key measuresAdjusted Net Operating ProfitTotal Shareholder Return (absolute TSR)Relative Total Shareholder Return (relative TSR)
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2026 | Mr. Michael Farrell | $16.2m | −$6.8m | $3.6m | $79 | $82 | $1.5bn |
| 2025 | Mr. Michael Farrell | $14.7m | $29.6m | $3.4m | $105 | $104 | $1.4bn |
| 2024 | Mr. Michael Farrell | $14.1m | $10.3m | $3.1m | $78 | $93 | $1.0bn |
| 2023 | Mr. Michael Farrell | $13.9m | $16.9m | $4.1m | $89 | $94 | $898.0m |
| 2022 | Mr. Michael Farrell | $11.7m | $4.4m | $3.6m | $85 | $84 | $779.0m |
Insiders and the CEO's stakeQuiet
- Chairman and CEO
- Michael J. Farrell
- Shares held
- 476,419
- At that filing's price
- ≈ $111.5m
- Latest Form 4
- Nov 11, 2026
Light activity: no buys, $8.7m sold in six months. 10 of 10 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldMichael J. FarrellChairman and CEO · 10b5-1 plan$6.5mNov 9, 2026
- SoldPeter C FarrellDirector · 10b5-1 plan$2.0mSep 2, 2026
- SoldMichael J RiderGlobal General Counsel · 10b5-1 plan$102kOct 23, 2026
- SoldWitte Jan DeDirector · 10b5-1 plan$102kNov 17, 2026
Leadership and governance on file
All 12 filings
- Aug 17, 2026Auditor change8-K 4.01
- Aug 17, 2026Leadership change8-K 5.02
- Apr 30, 2026Leadership change8-K 5.02
- Nov 20, 2025Leadership change8-K 5.02
- Aug 18, 2025Leadership change8-K 5.02
- Aug 1, 2025Leadership change8-K 5.02
- Aug 16, 2024Leadership change8-K 5.02
- Nov 9, 2023Leadership change8-K 5.02
- Mar 30, 2023Leadership change8-K 5.02
- Jan 26, 2023Leadership change8-K 5.02
- Jul 1, 2022Leadership change8-K 5.02
- May 11, 2022Leadership change8-K 5.02
Latest shareholder vote results: Nov 20, 2025, including the say-on-pay vote.
Where the money went
2021–2025: $1.8bn returned to owners in buybacks and dividends, 39% of net income, and $372.2m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.2bn | $3.6bn | $4.2bn | $4.7bn | $5.1bn |
| Net income | $474.5m | $779.0m | $898.0m | $1.0bn | $1.4bn |
| Stock-based pay | $63.9m | $65.3m | $71.1m | $80.2m | $91.7m |
| Buybacks | — | $0 | $0 | $150.0m | $300.0m |
| Dividends | $226.7m | $245.3m | $258.3m | $282.3m | $310.9m |
| Diluted shares | 146m | 147m | 147m | 148m | 147m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.